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I ntracranIal dural arteriovenous fistulas (DAVFs) are fed by dural arteries with drainage into the dural venous sinuses, meningeal veins, or cortical veins and account for 10%-15% of intracranial vascular malformations. 15 Hemorrhage is a severe complication of DAVFs and is closely related to the progression of the disease to venous ectasia and high-grade Borden-type DAVF. 5 Although surgery and endovascular intervention are primary treatments for DAVFs, the complexity of the angioarchitecture often limits the effectiveness of those therapies. Radiotherapy is a new treatment choice that seems to be relatively safe and effective, but outcomes are still related to cortical venous drainage and lesion size. 6 We recently found that chronic local hypoperfusion seems to be the main cause of angiogenesis in the dura mater, which leads to the formation of DAVFs. 1 2-Methoxyestradiol (2-ME) is a natural derivative of estradiol.
Recent oncology studies have shown that 2-ME is a safe antiangiogenic medicine that can be used to reduce tumor vasculature. 13 Considering the hypoxia-induced angiogenesis-related similarities between DAVFs and tumors, we speculated that 2-ME can also reduce the progression of DAVFs. In this study, we sought to test this hypothesis by using a rat model.
Methods
All experiments were approved by the Animal Care and Use Committee of Huashan Hospital, Fudan University. To exclude potential hormonal effects on DAVF formation and 2-ME intervention, only male Sprague-Dawley rats were used in the experiments; the rats weighed 350-400 g. All the rats were raised and kept in a specificpathogen-free (SPF) II room.
surgical and intervention protocols
All rats underwent the surgical procedure after an intraperitoneal injection of 1.5% pentobarbital sodium at a dose of 0.2 ml/100 g. The anesthetic was supplemented as needed during the procedure. All surgical procedures were performed using standard sterile techniques. DAVF formation was induced by using a modification of the model described by Chen et al. 1 First, the right anterior facial vein was ligated with 10-0 nylon sutures. Then, the proximal common carotid artery was anastomosed to the distal external jugular vein (EJV) in an end-to-end manner using 11-0 nylon interrupted sutures, which caused retrograde flow through the transverse sinus. The proximal segment of the EJV and the initial portions of the right external carotid and internal carotid arteries were obliterated separately. Through a second incision made below the left ear, the left terminal end of the transverse sinus was exposed and obliterated with bipolar coagulation. Afterward, a central craniotomy was performed from the coronal to the lambdoid suture and to 2.5 mm from the midline using an electronic drill. The superior sagittal sinus was exposed and ligated with 10-0 nylon sutures. A sketch of this model is shown in Fig. 1 upper.
The DAVF rats were randomly assigned to 1 of 3 groups based on the intervention protocol (18 rats in the late-intervention group and 24 rats each in the early-intervention and vehicle groups), and each group was then randomly divided into 4 subgroups according to the period between surgery and the time at which they were killed (4, 8, 12, or 16 weeks for the early-intervention and vehicle groups and 8, 12, or 16 weeks for the late-intervention group [6 rats each]). Rats in the early-intervention group received an intraperitoneal injection of 1% 2-ME (1:100 dimethyl sulfoxide/phosphate-buffered saline) solution at a dose of 0.06 ml/100 g/day starting immediately after surgery and continuing for 2 weeks. 2, 4 Each rat in the late-intervention group received its first injection 4 weeks after surgery, and the injections were continued daily for 2 weeks. In the vehicle group (blank control group), each rat was injected with solvent daily for 6 weeks. A diagram of the intervention protocol is shown in Fig. 1 lower. For the sham operation (n = 6), the EJV, common carotid artery, posterior facial vein, left terminal end of the transverse sinus, and superior sagittal sinus were exposed, but no further manipulations were performed. In total, 72 rats were included in the further experiments. For each group, 3 rats were used for immunohistochemical analysis, and 3 rats were used for Western blot analysis and real-time polymerase chain reaction (RT-PCR) analysis. All 6 rats in each group were used for plasma enzyme-linked immunosorbent assay examination.
immunohistochemistry
Dural tissue samples were fixed in 10% formalin, embedded in paraffin, sectioned at 4-mm thicknesses, and stained with anti-CD31 (rabbit monoclonal antibody [Abcam, HK Ltd.]), inhibitor of differentiation 1 (ID-1), hypoxia-inducible factor 1a (HIF-1a), vascular endothelial growth factor (VEGF), and matrix metalloproteinases 2 and/or 9 (MMP-2/9) antibodies (rabbit polyclonal antibodies [Abcam, HK Ltd.]). The secondary antibody was goat anti-rabbit immunoglobulin. Five random areas were selected in a low-power field (×100) in 5 sections, and the numbers of VEGF-, MMP-2/9-, HIF-1a-, and ID-1-positive cells were counted in ×200 fields. Microvessels marked by CD31 (lumen diameter < 10 cells) were measured in 5 random ×200 fields in 5 sections from each dura, and the microvessel density (MVD) was calculated. The immunohistochemical assessment of the microvessels was performed by 2 independent observers who were blinded to group assignments.
western blot analysis
The total, nuclear, and cytoplasmic proteins (100 mg) of the dural tissue were size-fractionated by using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Immobilon-P membranes (Millipore). The blotted membranes were incubated with primary antibodies against ID-1, HIF-1, VEGF, MMP-2/9, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Abcam, HK Ltd.), followed by incubation with a horseradish peroxidase-conjugated secondary antibody (Jackson Laboratories). The immunoreactivity was detected by using an enhanced chemiluminescence reaction system (Amersham Pharmacia Biotech). Plasma VEGF, MMP-2/9, and 2-ME levels were also measured by a sandwich enzyme-linked immunosorbent assay (R&D Systems) according to the manufacturer's protocols.
rt-pcr analysis
Total RNA was isolated from the dural tissues using TRIzol reagent (Gibco BRL). The mRNA expression levels of ID-1, HIF-1a, and GAPDH were evaluated by using RT-PCR analysis. The primers were as follows (forward/ reverse): ID-1, GGCTGCTACTCACGCCTCAA/RCA CTGATCTCGCCGTTCAGG; HIF-1a, GGCTGCTACT CACGCCTCAA/CACTGATCTCGCCGTTCAGG; and GAPDH, ACCACAGTCCATGCCATCAC/TCCACCAC CCTGTTGCTGTA. The melting curves and quantifications were analyzed by using LightCycler and Rel Quant software, respectively. All PCRs were performed in at least triplicate. The PCR products were subjected to electrophoresis on 1.5% agarose gels, scanned, and semiquantitated by using ImageQuant software (Kodak 1D V3.53).
statistical analysis
All data are presented as means ± SD. The data were analyzed using independent-sample t-tests and 1-way ANOVA. Any p value of < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS 16.0 for Windows.
results

2-Me suppressed the expression of angiogenic Factors and in the dura
We detected highly positive staining of angiogenic factors in the dural tissue of DAVF-model rats in the vehicle group from 4 to 16 weeks. It is notable that 2-ME was effective in the early and late stages of intervention. Immunohistochemical staining of VEGF was weak in all the dural vessels and surrounding tissue in both the early-and late-intervention groups (150.3 ± 46.4 vs 358.2 ± 66.2 mm 2 [p < 0.001] and 133.2 ± 44.5 vs 482.4 ± 88.6 mm 2 [p < 0.001]) around the drug-use window and was maintained approximately 2 weeks after the cessation of 2-ME. In the following weeks, both the early-and late-intervention groups were notably highly positive compared with those in the sham-operation group (Fig. 2) . Similar results were also found with ID-1, HIF-1a, and MMP-2/9 staining.
2-Me reduced Mvd in the dura
The densities of CD31-stained microvessels in the dura were calculated for the different groups and compared. Figure 3A shows that the MVDs continued to increase until the 8th week and then remained stable until 16 weeks in the vehicle-treated group. It is significant that the MVDs were suppressed in both the early-intervention and lateintervention groups. In the early-intervention group (at the 4th week), the MVD was 16.56 ± 4.80, approximately half the density in the vehicle group (35.33 ± 6.99, p = 0.001).
In the late-intervention group (at the 8th week), the MVD was 42.11 ± 4.70, approximately 65% that of the vehicle group (65.22 ± 7.38, p < 0.001).
angiogenic Factors suppressed by 2-Me in the dura and plasma
Western blot analysis was performed for semiquantitative assessment of the angiogenic factors in the dural tissue ( Figs. 3 and 4 ). As expected, the ID-1, HIF-1a, VEGF, and MMP-2/9 protein levels gradually increased in the dura after surgery in the vehicle group over those in the sham-operation group (Figs. 3C and D and 4B-D), and the protein levels became relatively stable after 8 weeks. In general, the angiogenic factors ID-1, HIF-1a, VEGF, and MMP-2/9 were suppressed by 2-ME in the early-intervention group at the 4th week and in the late-intervention group at the 8th week (vehicle-treated group >> early-and late-intervention groups > sham-operation group). In the early-intervention group at the 4th week, ID-1, HIF-1a, VEGF, MMP-2, and MMP-9 levels were significantly decreased compared with those in the vehicle group (2.15 ± 0.03 vs 3.20 ± 0.36 [p < 0.001]; 0.58 ± 0.07 vs 1.35 ± 0.01 [p = 0.001]; 3.38 ± 0.20 vs 5.27 ± 0.31 [p < 0.001]; 1.13 ± 0.17 vs 2.90 ± 0.48 [p = 0.004]; and 0.97 ± 0.07 vs 3.23 ± 0.36 [p = 0.003], respectively). In the late-intervention group at the 8th week, ID-1, HIF-1a, VEGF, MMP-2, and MMP-9 levels decreased to various extents compared with those in the vehicle group (1.04 ± 0.08 vs 7.57 ± 1.00 [p < 0.001]; 0.89 ± 0.01 vs 4.54 ± 0.36 [p = 0.002]; 5.05 ± 0.22 vs 18.03 ± 1.51 [p < 0.001]; 1.58 ± 0.19 vs 5.59 ± 0.07 [p = 0.001]; and 1.77 ± 0.08 vs 5.86 ± 0.36 [p = 0.004], respectively). For rats in the other intervention groups that were killed at the 12th or 16th week, although 2-ME injections reduced their angiogenic factors to levels comparable to those of the corresponding vehicle-treated groups, the protein levels were still much higher than those in the sham-operation group (vehicle-treated group > early-and late-intervention groups >> sham-operation group). In the plasma, VEGF levels were significantly suppressed in both the early-and late-intervention groups at the 4th, 8th, and 12th weeks after surgery (Fig. 5A ). However, MMP-2/9 levels in the plasma were not remarkably decreased ( Fig. 5B and C) . The 2-ME concentrations (all measured before the rats were killed) in the plasma showed no differences among any of the groups (Fig. 5D ).
2-Me suppressed mrNa levels of angiogenic Factors and the time effects of 2-Me on venous hypertension-induced angiogenesis
To analyze the time effects of 2-ME on this DAVF model, we examined the mRNA levels of ID-1 and HIF-1a in the dura (Fig. 6 ). In the vehicle-treated group, the relative levels of ID-1 and HIF-1a mRNA continued to increase to their peak values at the 8th week. Then, during the following weeks, ID-1 mRNA levels remained relatively stable, whereas HIF-1a mRNA levels decreased. Compared with those in the vehicle group, ID-1 and HIF-1a mRNA and protein levels in both the early-and lateintervention groups were decreased significantly after the 2-ME injection. 2-Methoxyestradiol was proven to have an antiangiogenesis effect on mRNA and protein levels during the drug-use window, which lasted up to approximately 2 weeks after drug cessation.
discussion
The natural prognosis of DAVF is closely related to the flow rate through the fistula and retrograde flow pattern of the disease, and dural angiogenesis is a major patho- logical change. In 1997, Lawton et al. 16 first raised the angiogenesis hypothesis for the formation of DAVFs and highlighted venous hypertension, cerebral ischemia, and tissue hypoxia. Zhu et al. 21 found that the levels of angiogenic factor HIF-1a and downstream VEGF in the brain could be increased by nonischemic venous hypertension. Our recent study results indicated that venous hypertension might induce chronic regional hypoperfusion and VEGF MMP-9 expression, thus promoting angiogenesis. 1 A modified rat DAVF model was then created on the basis of these findings. In this study, we confirmed that the angiogenic factors ID-1, HIF-1a, VEGF, and MMP-2/9 and MVD can be induced by venous hypertension and regional hypoperfusion, which might contribute to dural angiogenesis and the initiation of arteriovenous shunting. It is our hope that controlling the angiogenic progress of DAVF lesions provides a new treatment option.
The angiogenesis process is regulated by various angiogenic factors. VEGF and MMPs are key angiogenic factors that can be increased by hypoxia-ischemia, which participate in endothelial cell proliferation and migration. 7, 20 VEGF and MMPs can be induced by HIF-1 by regulating gene transcription to adapt to tissue hypoxia. 11 As a member of the ID protein family, ID-1 is believed to regulate cell differentiation, cell-cycle progression, senescence, and apoptosis. 18 Kim et al. 12 found that ID-1 can enhance the stability and activity of HIF-1a by cross-talking in human endothelial cells, thus inducing VEGF expression.
The etiology of DAVF has long been known to relate to sex hormones. A clinical study revealed that serum estradiol levels in patients with DAVF were lower than levels in control patients. 14 Also, there is a predilection for highergrade DAVFs (according to their Borden type) in males. As a sex hormone, estradiol does not have a direct antiangiogenic effect; however, its metabolite 2-ME is a potent antiangiogenic agent. 4 Compared with estradiol, this derivative does not exhibit direct estrogenic activity in vitro or in vivo because of its low binding affinity to estrogen receptors. 8 2-Methoxyestradiol has been shown to reduce vascular endothelial cell proliferation and migration. Mabjeesh et al. 17 demonstrated that 2-ME can downregulate HIF-1a on the protein level and can reduce transcriptional activity in tumors. Huh et al. 9 confirmed that ID-1 was negatively regulated by 2-ME in tumor and vascular endothelial cells with a dose-effect relationship. Therefore, clinical trials have been approved for patients with cancer. 3, 19 According to a Phase I clinical trial, the maximal 2-ME administration dose is 1000 mg/day, and its half-life is 10 hours in the human body with a daily dose. 10 Based on previous in vivo studies, 2,4 2-ME injection at a dose of 60 mg/kg per day was considered safe for the rats in this study.
We have shown that 2-ME downregulated ID-1 mRNA Fig. 5 . VEGF, MMP-2/9, and 2-ME levels in plasma (detected by enzyme-linked immunosorbent assays). a: Plasma levels of VEGF, which were significantly suppressed in both the early- and late-intervention groups at the 4th, 8th, and 12th weeks. b: Plasma levels of MMP-2, which were not significantly suppressed by 2-ME in either the early- or late-intervention group at the 4th, 8th, or 12th week. c: Plasma levels of MMP-9, which were suppressed only by 2-ME in the early-intervention group at the 4th week. d: Plasma 2-ME concentrations, which showed no differences among all the groups before the time at which the rats were killed. *p < 0.05 versus the vehicle-treated group (n = 6). and protein levels induced by local venous hypertension and regional hypoperfusion. In addition, 2-ME consistently suppressed angiogenic factors in this pathway to various degrees, which led to a decrease of MVD in the dura. Ten weeks after 2-ME cessation, the angiogenic factor levels remained almost half of the levels in the vehicle groups but were much higher than that in the sham group and the MVD could no longer be reduced. That the plasma 2-ME levels at the end-point detection had already decreased to the baseline in the intervention groups implies a persistent requirement for 2-ME administration to control angiogenesis. Because few adverse effects have been identified, long-term administration of 2-ME should be acceptable. In this study, we could not arbitrarily determine the effectiveness of 2-ME on human DAVF. First, although we tried to replicate the pathogenesis of human DAVF and allowed an assessment of the effect of 2-ME in a rat model, the model we used could only partly represent the features of human DAVF. Second, 2-ME was shown to have a doseeffect relationship with the expression of antiangiogenic factors, and the maximum in vivo dose reached up to 150 mg/kg. 9 The 2-ME dose we used in this study was 60 mg/ kg per day and lasted for 2 weeks, so the long-term effect of 2-ME on DAVF formation was not assessed.
conclusions
Despite the limitations of this study, our findings collectively imply a potential therapeutic value of 2-ME in this rat DAVF model. Further investigations are needed to determine its long-term effect on DAVF.
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